Rainer Hamacher, Kim M Pabst, Phyllis F Cheung, Christoph E Heilig, Jennifer Hüllein, Sven-Thorsten Liffers, Sabrina Borchert, Pedro Fragoso Costa, Benedikt M Schaarschmidt, Lukas Kessler, Monika A Miera, Margret Droste, Merve Akbulut, Johanna Falkenhorst, Fadi Zarrad, Karina Kostbade, Ilektra A Mavroeidi, Hanno Glimm, Lale [...]

Xiang Li, Na Lu, Lili Lin, Yiwen Chen, Shuye Yang, Huatao Wang, Xinyuan Liu, Chengyi Wu, Xing Xue, Xinhui Su, Xueli Bai, Tingbo Liang Abstract Accurate diagnosis and staging are crucial for selecting treatment for patients with pancreatic ductal adenocarcinoma (PDAC). The desmoplastic responses [...]

Ling Chen, Shan Zheng, Linying Chen, Sunwang Xu, Kunlin Wu, Lingjun Kong, Jiajie Xue, Xiangjin Chen, Weibing Miao, Youzhi Zhu Abstract 68Ga-labeled fibroblast activation protein inhibitor (68Ga-FAPI) PET/CT has demonstrated promising clinical results, with a higher SUVmax and tumor-to-background ratio (TBR) in breast cancer [...]

Aashna Karbhari, Sherly Mosessian, Kamaxi H. Trivedi, Frank Valla Jr, Mark Jacobson, Mark J. Truty, Nandakumar G. Patnam, Diane M. Simeone, Elcin Zan, Tracy Brennan, Hongli Chen, Phillip H. Kuo, Ken Herrmann, Ajit H. Goenka Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is a lethal [...]

Ling Chen, Shan Zheng, Linying Chen, Sunwang Xu, Kunlin Wu, Lingjun Kong, Jiajie Xue, Xiangjin Chen, Weibing Miao and Youzhi Zhu Abstract 68Ga-labeled fibroblast activation protein inhibitor (68Ga-FAPI) PET/CT has demonstrated promising clinical results, with a higher SUVmax and tumor-to-background ratio (TBR) in breast cancer [...]

Lukas Kessler, Nader Hirmas, Kim M. Pabst, Rainer Hamacher, Justin Ferdinandus, Benedikt M. Schaarschmidt, Aleksandar Milosevic, Michael Nader, Lale Umutlu, Waldemar Uhl, Anke Reinacher-Schick, Celine Lugnier, David Witte, Marco Niedergethmann, Ken Herrmann, Wolfgang P. Fendler and Jens T. Siveke Abstract The fibroblast activation protein [...]

Weizhi Xu, Jiayu Cai, Tianxing Peng, Tinghua Meng, Yizhen Pang, Long Sun, Hua Wu, Jingjing Zhang, Xiaoyuan Chen and Haojun Chen Abstract Fibroblast activation protein is overexpressed in the stroma of several cancer types. 18F-fibroblast activation protein inhibitor (FAPI)–74 is a PET tracer with [...]

Emil Novruzov1, Frederik L Giesel1,2, Yuriko Mori1, Peter L Choyke3, Mardjan Dabir1, Eduards Mamlins1, Dominik Schmitt1, Christina Antke1, Claudio Pinto4, Cristian Soza-Ried5,6, Rene Fernandez5, Horacio Amaral5,6, Vasko Kramer5,6, Leonardo Badinez7 Abstract Background: Radiolabeled fibroblast activation protein (FAP) ligands, a novel class of tracers for PET/CT [...]

Meiqi Wu1, Yanyu Wang2, Qiao Yang1, Xuezhu Wang1, Xu Yang2, Haiqun Xing1, Xinting Sang2, Xiang Li3, Haitao Zhao2, Li Huo4 Abstract Fibroblast activation protein contributes to immunosuppression and resistance to immunotherapies. This study aimed to compare baseline 68Ga-labeled fibroblast activation protein inhibitor (68Ga-FAPI) PET/CT and 18F-FDG [...]

Alessio Rizzo1, Manuela Racca1, Federico Garrou2, Elisabetta Fenocchio3, Luca Pellegrino4, Domenico Albano5, Francesco Dondi5, Francesco Bertagna5, Salvatore Annunziata6, Giorgio Treglia7,8,9 Abstract Various papers have introduced the use of positron emission tomography (PET) with [68Ga]Ga-radiolabeled fibroblast-activation protein inhibitor (FAPi) radiopharmaceuticals in different subtypes of gastric [...]